Mga Batayang Estadistika
| CIK | 948320 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to LifeMD, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 21, 2025 |
Exhibit 16.1 August 21, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by LifeMD, Inc. under Item 4.01 of its Form 8-K dated August 21, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of LifeMD, Inc. contained therein. Very tr |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact n |
|
| August 5, 2025 |
LifeMD Reports Second Quarter 2025 Results Exhibit 99.1 LifeMD Reports Second Quarter 2025 Results ● Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 million ● Telehealth revenue increased 30% to $48.6 million; telehealth adjusted EBITDA rose 560% to $3.4 million ● Generated more than $8 million of operating cash flow ● Paid down $2.1 million of senior debt, exited the quarter with $36.2 millio |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| July 31, 2025 |
Exhibit 10.4 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT THIS THIRD AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Third Amendment”) is entered into as of July 27, 2025 (the “Third Amendment Effective Date”) by and between Shayna Dray, an individual and resident of the State of Rhode Island, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Corporat |
|
| July 31, 2025 |
Confidential Offer Letter, dated April 14, 2021 between LifeMD, Inc. and Shayna Webb Dray Exhibit 10.1 |
|
| July 31, 2025 |
Exhibit 10.3 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of May 7, 2024 (the “Second Amendment Effective Date”) by and between Shayna Dray, an individual and resident of the State of Rhode Island, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Corpor |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 31, 2025 |
LifeMD Names COO and Promotes Two Executives Exhibit 99.1 LifeMD Names COO and Promotes Two Executives NEW YORK, July 31, 2025 – LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services, today announced the appointment of Shayna Webb Dray as its Chief Operating Officer. Ms. Webb Dray, an accomplished operations and supply chain executive with over 15 years of experience, has been an integral part of LifeMD’s growth, mos |
|
| July 31, 2025 |
Exhibit 10.5 EXHIBIT A LIFEMD, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is made as of July 27, 2025 (the “Grant Date”) between LifeMD, Inc. (the “Company”), and Shayna Dray (the “Employee”). WHEREAS, the Company desires to grant the Employee, Restricted Stock Units of the Company’s Common Stock, $0.01 par value (“RSUs”), subject to certain restrictions as set fo |
|
| July 31, 2025 |
Exhibit 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “First Amendment”) is entered into as of November 8, 2023 (the “First Amendment Effective Date”) by and between Shayna Dray, an individual and resident of the State of Rhode Island, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Corpo |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 6, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact |
|
| May 6, 2025 |
LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance Exhibit 99.1 LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance · Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70% · Adjusted EBITDA increased to $8.7 million from $0.1 million in the year-ago period · Telehealth adjusted EBITDA increased to $5.3 million from a loss of $1.3 million in the year-ago period · GAAP net income of $0.6 |
|
| April 29, 2025 |
Exhibit 99.1 Apr 28, 2025 07:00am LifeMD Acquires Women’s Health Provider Optimal Human Health MD to Accelerate Entry into the Women’s Health Market NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the acquisition of key assets from Optimal Human Health MD (“Optimal”), a nationwide women’s health virtual c |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 25, 2025 |
Letter from Marcum LLP, to the Securities and Exchange Commission, dated April 25, 2025. Exhibit 16.1 April 25, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by LifeMD, Inc. under Item 4.01 of its Form 8-K dated April 24, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of LifeMD, Inc., contained therein. Very tru |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-39785 LIFEMD, INC. (E |
|
| March 11, 2025 |
Employment Agreement, dated December 13, 2021, between Dennis Wijnker and LifeMD, Inc. Exhibit 10.68 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of December 13th, 2021, (the “Effective Date”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), having corporate headquarters at 236 Fifth Avenue, Suite 400, New York, NY 10001, and Dennis Wijnker, an individual and resident of the State of California with an address at [***] (the “ |
|
| March 11, 2025 |
Exhibit 10.43 FOURTH RENEWED DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of December 2, 2024 (the “Agreement”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), and John Strawn, an individual with an address of [***] (the “Director”). WHEREAS, the Company originally appointed the Director on April 20, 2011; re-entered into an agreement with Director for each subsequen |
|
| March 11, 2025 |
LifeMD, Inc. Insider Trading Policy Exhibit 19 LIFEMD, INC. INSIDER TRADING POLICY This Insider Trading Policy (“Policy”) sets forth the policies of LifeMD, Inc. (the “Company”) on trading and causing the trading of securities while in possession of confidential information. Purpose The Board of Directors of the Company has adopted this Policy to provide guidance to Insiders (as defined below) about trading in the Company’s securiti |
|
| March 11, 2025 |
Exhibit 10.44 THIRD RENEWED DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of December 6, 2024 (the “Agreement”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), and Dr. Joseph DiTrolio, an individual with an address of [***] (the “Director”). WHEREAS, the Company originally appointed the Director on or around September 4, 2014; re-entered into an agreement with Directo |
|
| March 11, 2025 |
Exhibit 21.1 Subsidiaries of LifeMD, Inc. Subsidiary Name Jurisdiction of Incorporation WorkSimpli Software LLC Puerto Rico |
|
| March 11, 2025 |
Employment Agreement, dated June 20, 2023, between LifeMD, Inc. and Shane Biffar Exhibit 10.79 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of June 20, 2023, (the “Effective Date”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), having corporate headquarters at 236 Fifth Avenue, Suite 400, New York, NY 10001, and Shane Biffar, an individual and resident of the State of New York with an address at [***] (the “Employee”) |
|
| March 10, 2025 |
LifeMD Reports Fourth Quarter 2024 Results Exhibit 99.1 LifeMD Reports Fourth Quarter 2024 Results ● Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60% ● Adjusted EBITDA increased 78% to $9.0 million ● Telehealth adjusted EBITDA increased 396% to $5.9 million ● Full-year cash flow from operations increased 99% to $17.5 million and generated positive full-year net cash flow ● Exited 2024 with |
|
| March 10, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 31, 2025 |
CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. §200.83 BY LIFEMD, INC. LIFEMD, INC. 236 Fifth Avenue, Suite 400 New York, New York 10001 VIA FEDERAL EXPRESS AND SECURE E-MAIL January 31, 2025 Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Christie Wong Ms. Li Xiao Mr. Micha |
|
| January 13, 2025 |
Exhibit 4.13 |
|
| January 13, 2025 |
Third Renewed Director Agreement, dated August 25, 2023, between LifeMD, Inc. and John Strawn Exhibit 4.37 |
|
| January 13, 2025 |
Exhibit 4.11 |
|
| January 13, 2025 |
As filed with the Securities and Exchange Commission on January 13, 2025 As filed with the Securities and Exchange Commission on January 13, 2025 Registration No. |
|
| January 13, 2025 |
Exhibit 4.34 |
|
| January 13, 2025 |
Exhibit 4.30 |
|
| January 13, 2025 |
Second Renewed Director Agreement, dated November 22, 2022, between LifeMD, Inc. and John Strawn Exhibit 4.36 |
|
| January 13, 2025 |
Employment Agreement, dated December 13, 2021, between LifeMD, Inc. and Dennis Wijnker Exhibit 4.29 |
|
| January 13, 2025 |
Fourth Renewed Director Agreement, dated December 2, 2024, between LifeMD, Inc. and John Strawn Exhibit 4.38 |
|
| January 13, 2025 |
Exhibit 4.41 |
|
| January 13, 2025 |
Exhibit 4.24 |
|
| January 13, 2025 |
Exhibit 4.43 |
|
| January 13, 2025 |
Exhibit 4.40 |
|
| January 13, 2025 |
Second Renewed Director Agreement, dated July 1, 2022, by and between LifeMD, Inc. and Roberto Simon Exhibit 4.32 |
|
| January 13, 2025 |
Exhibit 4.12 |
|
| January 13, 2025 |
Exhibit 4.44 |
|
| January 13, 2025 |
Exhibit 4.33 |
|
| January 13, 2025 |
Exhibit 4.14 |
|
| January 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) LIFEMD, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities |
|
| December 31, 2024 |
Exhibit 10.1 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of December 24, 2024 (the “Second Amendment Effective Date”) by and between Justin Schreiber, an individual and resident of the State of Pennsylvania, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Dela |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2024 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| December 12, 2024 |
CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. §200.83 BY LIFEMD, INC. LIFEMD, INC. 236 Fifth Avenue, Suite 400 New York, New York 10001 VIA FEDERAL EXPRESS AND SECURE E-MAIL December 12, 2024 Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Christie Wong Mr. Michael Fay Re: |
|
| November 14, 2024 |
LFMD / LifeMD, Inc. / Divisadero Street Capital Management, LP Passive Investment SC 13G/A 1 d1152814813g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* LifeMD, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 53216B104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Ex |
|
| November 7, 2024 |
Exhibit 10.6 FIRST AMENDMENT TO CONSULTING SERVICES AGREEMENT This First Amendment To Consulting Services Agreement (“First Amendment”) is made effective as of July 17, 2024 (the “First Amendment Effective Date”), by and between Robert Jindal, having an address at [***] (the “Consultant”) and LifeMD, Inc., a corporation with an address of 236 Fifth Avenue, Suite 400, New York, NY 10001 (the “Compa |
|
| November 7, 2024 |
Exhibit 10.2 FIRST AMENDMENT TO THE LEASE AGREEMENT (“AGREEMENT”) BETWEEN Running Pump Business Center, LP, “LANDLORD” AND LifeMD, “TENANT” FOR A PORTION OF THE PROPERTY AT 499 Running Pump Road Township of East Hempfield DATED February 20, 2024 It is mutually understood and agreed by all parties that this Agreement shall be amended as follows: 1. In addition to the Tenant Work outlined in Article |
|
| November 7, 2024 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 LEASE AGREEMENT This Lease (“Lease”) is made and entered into as of February 20, 2024 (the “Effective Date”) by and between the Landlord and the Tenant named below. ARTICLE 1. Definitions and Certain Basic Provisions. 1.1 (a) “Landlord”: RUNNING PUMP BUSINESS CENTER, LP, a Pennsylvania Limited Partnership (b) “Managing Agent”: Running Pump Business Center, LLC (c) |
|
| November 7, 2024 |
Exhibit 10.5 OFFICE LEASE ******************************* FRONT STREET - BROOKFIELD, LLC (Lessor) and LIFEMD, INC. (Lessee) TABLE OF CONTENTS Paragraph Number Subject Page 1 Tenant Improvements 1 2 Lease Term; Security Deposit 2 3 Rental 3 4 Maintenance Responsibilities; Operating Expenses 5 5 Taxes & Assessments 6 6 Services by Lessor 7 7 Alterations 7 8 Use and Occupancy 8 9 Insurance 9 10 Fire |
|
| November 7, 2024 |
Exhibit 10.3 SECOND AMENDMENT TO THE LEASE AGREEMENT (“AGREEMENT”) BETWEEN Running Pump Business Center, LP, “LANDLORD” AND LifeMD, “TENANT” FOR A PORTION OF THE PROPERTY AT 499 Running Pump Road Township of East Hempfield DATED February 20, 2024 It is mutually understood and agreed by all parties that this Agreement shall be amended as follows: 1. “TENANT” party is now identified with increased s |
|
| November 7, 2024 |
Exhibit 10.4 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE dated as of May 6th, 2024 (this “Amendment”) between 236 FIFTH LEASEHOLD LLC, a Delaware limited liability company having an office c/o Kaufman Management Company, LLC, 450 Seventh Avenue, New York, New York 10123 (“Landlord”), and LIFEMD, INC., a Delaware corporation having an office at 236 Fifth Avenue, New York, New York 10001 |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| October 25, 2024 |
LIFEMD, INC. 236 Fifth Avenue, Suite 400 New York, New York 10001 LIFEMD, INC. 236 Fifth Avenue, Suite 400 New York, New York 10001 October 25, 2024 VIA EDGAR SUBMISSION Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Christie Wong Mr. Michael Fay Re: LifeMD, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 File No. 001-39785 Dear |
|
| August 13, 2024 |
LIFEMD, INC. 1,284,892 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279860 PROSPECTUS LIFEMD, INC. 1,284,892 Shares of Common Stock This prospectus relates to the resale (the “Offering”), from time to time, of up to 1,284,892 shares (the “Shares”) of our common stock, par value $0.01 per share (“Common Stock”), held by the Selling Stockholders identified in this prospectus under “Selling Stockholders”. 1,224,42 |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact n |
|
| July 16, 2024 |
LifeMD, Inc. 226 Fifth Avenue, Suite 400 New York, NY 10001 LifeMD, Inc. 226 Fifth Avenue, Suite 400 New York, NY 10001 July 16, 2024 VIA EDGAR U.S. Securities & Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Juan Grana Re: LifeMD, Inc. Registration Statement on Form S-3, as amended Filed May 31, 2024 File No. 333-279860 Dear Mr. Grana: In accordance with Rule 461 of the Securities Act of 1933, as a |
|
| July 16, 2024 |
LifeMD, Inc. 226 Fifth Avenue, Suite 400 New York, NY 10001 LifeMD, Inc. 226 Fifth Avenue, Suite 400 New York, NY 10001 July 16, 2024 VIA EDGAR U.S. Securities & Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Juan Grana Re: LifeMD, Inc. Registration Statement on Form S-3, as amended Filed June 7, 2024 File No. 333-280033 Dear Mr. Grana: In accordance with Rule 461 of the Securities Act of 1933, as a |
|
| July 5, 2024 |
As filed with the Securities and Exchange Commission on July 5, 2024 As filed with the Securities and Exchange Commission on July 5, 2024 Registration No. |
|
| July 5, 2024 |
Exhibit 4.5 |
|
| July 5, 2024 |
Description of verbal agreement between Immudyne, Inc. and Strawn Pickens LLP dated March 9, 2012 Exhibit 4.6 Description of Verbal Agreement between Immudyne, Inc. and Strawn Pickens LLP John R. Strawn, Jr., is a founding partner of Strawn Pickens LLP. During 2011, Strawn Pickens LLP provided legal services to Immudyne, Inc., a predecessor of LifeMD, Inc. On March 9, 2012, Immudyne issued 80,000 shares to Strawn Pickens LLP in settlement of $70,000 in outstanding fees for these legal services |
|
| July 5, 2024 |
As filed with the Securities and Exchange Commission on July 5, 2024 As filed with the Securities and Exchange Commission on July 5, 2024 Registration No. |
|
| July 5, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) LIFEMD, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities |
|
| July 5, 2024 |
As filed with the Securities and Exchange Commission on July 5, 2024 As filed with the Securities and Exchange Commission on July 5, 2024 Registration No. |
|
| June 18, 2024 |
Third Amended and Restated 2020 Equity and Incentive Plan Exhibit 10.1 LIFEMD, INC. THIRD AMENDED AND RESTATED 2020 EQUITY AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN: DEFINITIONS The name of the plan is the LIFEMD, INC. THIRD AMENDED AND RESTATED 2020 EQUITY AND INCENTIVE PLAN (the “Plan”). The purpose of the Plan is to encourage, retain and enable the officers, employees, directors, Consultants and other key persons of LIFEMD, INC., a Del |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) LIFEMD, INC. (Exact name of registrant as specified in its charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly |
|
| June 7, 2024 |
As filed with the Securities and Exchange Commission on June 7, 2024 As filed with the Securities and Exchange Commission on June 7, 2024 Registration No. |
|
| May 31, 2024 |
Exhibit 4.12 Execution Copy REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 11, 2023, is made and entered into by and between LifeMD, Inc., a Delaware corporation (the “Company”) and Jason Pharmaceuticals, Inc., a Maryland corporation (“Holder”). RECITALS WHEREAS, pursuant to the terms of that certain Stock Purchase Agreement (the “Purchase |
|
| May 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) LIFEMD, INC. (Exact name of registrant as specified in its charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
Exhibit 4.11 Execution Copy STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”) is dated as of December 11, 2023, between LifeMD, Inc., a Delaware corporation (the “Company”), and Jason Pharmaceuticals, Inc., a Maryland corporation (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 2, 2024 |
Restricted Stock Award Agreement, dated April 26, 2024, between LifeMD, Inc. and Calum MacRae Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT DIRECTORS THIS RESTRICTED STOCK AWARD (this “Agreement”) is granted as of April 26, 2024 (the “Grant Date”), and reflected in this RESTRICTED STOCK AWARD AGREEMENT (the “Agreement”) between LifeMD, Inc. (the “Company”), and Dr. Calum MacRae (the “Director”). WHEREAS, the Company desires to grant the Director, shares of the Company’s Common |
|
| May 2, 2024 |
Director Agreement, dated April 26, 2024, between LifeMD, Inc. and Calum MacRae Exhibit 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of April 26, 2024 (the “Agreement”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), and Dr. Calum MacRae, an individual with an address of 34 Yarmouth Road, Wellesley Hills, MA 02481 (the “Director”). WHEREAS, the Company and the Director desire to enter with respect to the appointment of the Director; WHEREAS |
|
| May 2, 2024 |
LifeMD Appoints Dr. Calum MacRae to its Board of Directors Exhibit 99.1 LifeMD Appoints Dr. Calum MacRae to its Board of Directors NEW YORK, April 29, 2024 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. “We are delighted to welcome Dr. MacRae t |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) LIFEMD, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securit |
|
| March 15, 2024 |
Stock Option Agreement, dated April 20, 2011, between ImmuDyne, Inc. and John R. Strawn Exhibit 4.17 |
|
| March 15, 2024 |
Confidential Employment Term Sheet, dated June 23, 2020, between Kevin Veal and LifeMD, Inc. Exhibit 4.19 |
|
| March 15, 2024 |
Stock Option Agreement, dated April 20, 2011, between ImmuDyne, Inc. and John R. Strawn Exhibit 4.18 |
|
| March 15, 2024 |
First Amendment to Employment Agreement, dated July 5, 2021, between Kevin Veal and LifeMD, Inc. Exhibit 4.20 |
|
| March 15, 2024 |
As filed with the Securities and Exchange Commission on March 15, 2024 As filed with the Securities and Exchange Commission on March 15, 2024 Registration No. |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39785 LIFEMD, INC. (E |
|
| March 11, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97 |
|
| March 11, 2024 |
Exhibit 21.1 Subsidiaries of LifeMD, Inc. Subsidiary Name Jurisdiction of Incorporation WorkSimpli Software LLC Puerto Rico Cleared Technologies, PBC Delaware Springbox Technologies LLC Delaware Taylor Technologies Inc Delaware |
|
| March 11, 2024 |
Separation Agreement dated March 9, 2024 between Brad Roberts and LifeMD, Inc. Exhibit 10.110 |
|
| February 14, 2024 |
LFMD / LifeMD, Inc. / Divisadero Street Capital Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 21, 2023 |
Exhibit 4.21 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. As of August 1st, 2020 CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT OFFER Set forth below is an outline of the management compensation terms by which the undersigned |
|
| December 21, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) LIFEMD, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securit |
|
| December 21, 2023 |
As filed with the Securities and Exchange Commission on December 21, 2023 As filed with the Securities and Exchange Commission on December 21, 2023 Registration No. |
|
| December 21, 2023 |
Non-Qualified Stock Option Agreement, dated November 9, 2021, between LifeMD, Inc. and Kenny Bae Exhibit 4.26 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT EMPLOYEE THIS NON-QUALIFIED STOCK OPTION AGREEMENT (the “Agreement”) entered into as of the November 9, 2021 (the “Me |
|
| December 21, 2023 |
Exhibit 4.22 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT TERM SHEET Set forth below is an outline of the compensation terms by which the undersigned parties agree to abide by whe |
|
| December 21, 2023 |
Exhibit 4.25 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT EMPLOYEE THIS NON-QUALIFIED STOCK OPTION AGREEMENT (the “Agreement”) entered into as of the October 8, 2021 (the “Mem |
|
| December 21, 2023 |
Stock Option Agreement, dated January 2, 2017, between ImmuDyne, Inc. and John R. Strawn Exhibit 4.16 STOCK OPTION AGREEMENT THIS AGREEMENT is entered into this 2nd day of January, 2017 between ImmuDyne, Inc., a Delaware corporation (the “Company”) and John R. Strawn (“Option Holder/Holder”). WHEREAS, the Board of Directors of the Company has this day authorized the issuance of the option set forth below to Option Holder. NOW, THEREFORE, in consideration of the mutual covenants herein |
|
| December 21, 2023 |
Exhibit 4.24 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT TERM SHEET Set forth below is an outline of the compensation terms by which the undersigned parties agree to abide by whe |
|
| December 21, 2023 |
Employment Agreement, dated December 13, 2021, between LifeMD, Inc. and Dennis Wijnker Exhibit 4.27 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of December 13th, 2021, (the “Effective Date”), by and between LifeMD, Inc., a Delawa |
|
| December 21, 2023 |
Exhibit 4.18 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. September 10, 2018 CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT OFFER LETTER Name: Ernie Ibarra (the “Employee”) Position: Lead Web Developer Base Salary: $[***] from |
|
| December 21, 2023 |
Employment Agreement, dated October 1, 2019, between Conversion Labs, Inc. and Ernie Ibarra Exhibit 4.19 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), effective as of October 1, 2019, is entered into between Conversion Labs, Inc., a Delaware corporati |
|
| December 21, 2023 |
Employment Agreement, dated October 1, 2019, between Conversion Labs, Inc. and Michael Angulo Exhibit 4.29 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), effective as of October 1, 2019, is entered into between Conversion Labs, Inc., a Delaware corporati |
|
| December 21, 2023 |
Exhibit 4.23 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. As of September 28th, 2020 CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT & INVESTMENT TERM SHEET Set forth below is an outline of the management compensation terms by |
|
| December 21, 2023 |
Exhibit 4.28 BONUS AGREEMENT This AGREEMENT (“Agreement’’) is dated as of August 16, 2017 between IMMUDYNE, INC., a Delaware corporation (the “Company”), and Brian Schreiber DBA BV Global Fulfillment, LLC (“Independent Contractor’’). The Company and the Independent Contractor are hereinafter sometimes referred to collectively as the “Parties” and individually as a “Party.” WITNESSETH: WHEREAS, the |
|
| December 21, 2023 |
Exhibit 4.20 Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. As of February 10th, 2020 CONVERSION LABS, INC. CONFIDENTIAL EMPLOYMENT & INVESTMENT TERM SHEET Set forth below is an outline of the management compensation terms by w |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| December 13, 2023 |
Exhibit 99.1 LifeMD and Medifast Partner to Offer Transformative Weight Management Solution Collaboration will integrate LifeMD’s telehealth platform and GLP-1 offering for medically qualified patients with OPTAVIA Coach-guided, healthy lifestyle solution Medifast has invested $20 million, including a $10 million payment in support of the collaboration and a $10 million purchase of LifeMD common s |
|
| November 14, 2023 |
Exhibit 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “First Amendment”) is entered into as of November 13, 2023 (the “First Amendment Effective Date”) by and between Justin Schreiber, an individual and resident of the State of Pennsylvania, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware |
|
| November 14, 2023 |
Employment Agreement dated April 1, 2022 between Justin Schreiber and LifeMD, Inc. Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of April 1, 2022, (the “Effective Date”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), having corporate headquarters at 236 Fifth Avenue, Suite 400, New York, NY 10001, and Justin Schreiber, an individual and resident of Puerto Rico with an address at 12 Dorado Beach East, Dorado, |
|
| November 14, 2023 |
Restricted Stock Award Agreement dated November 13, 2023 between Justin Schreiber and LifeMD, Inc. Exhibit 10.3 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is made effective as of November 13, 2023 (the “Grant Date”) between LifeMD, Inc. (the “Company”) and Justin Schreiber (the “Employee”). WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common Stock, $0.01 par value (“Shares”), subject to certain restrictions as set forth in this |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Ex |
|
| November 8, 2023 |
Exhibit 1.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT AND SUPPLEMENT This First Amendment to Loan and Security Agreement and Supplement (this “Amendment”) is dated as of September 26, 2023, and is entered into by and among LIFEMD, Inc., a Delaware corporation (the “Borrower”) and AVENUE VENTURE OPPORTUNITIES FUND II, L.P., (“Avenue 2”), as a lender, and AVENUE VENTURE OPPORTUNITIES FUND, L.P. |
|
| November 8, 2023 |
Restricted Stock Award Agreement dated July 26, 2023 between Nicholas Alvarez and LifeMD, Inc Exhibit 10.4 LIFEMD, INC. AMENDED AND RESTATED RESTRICTED STOCK AWARD AGREEMENT THIS AMENDED AND RESTATED AGREEMENT (this “Amended Agreement”) is made effective as of July 26, 2023 (the “Grant Date”) between LifeMD, Inc. (the “Company”) and Nicholas Alvarez (the “Employee”). WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common Stock, $0.01 par value (“Shares”), subjec |
|
| November 8, 2023 |
Exhibit 10.3 AMENDED AND RESTATED FIRST AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED FIRST AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amended and Restated First Amendment”) is entered into as of July 26, 2023 (the “Amended and Restated First Amendment Effective Date”) by and between Nicholas Alvarez, an individual and resident of the S |
|
| October 6, 2023 |
LFMD / LifeMD Inc / Divisadero Street Capital Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| August 10, 2023 |
Investor Presentation dated August 2023 Exhibit 99.1 |
|
| August 9, 2023 |
Consulting Services Agreement, dated June 14, 2023, by and between the Company and Naveen Bhatia Exhibit 10.4 SECOND CONSULTING SERVICES AGREEMENT This Second Consulting Services Agreement (“Consulting Agreement” or the “Agreement”) is made effective as of June 14, 2023 (the “Effective Date”), by and between Naveen Bhatia, an individual with an address at 1327 Bay Head Road, Annapolis, MD 21409 (the “Consultant”) and LifeMD, Inc., a corporation with an address of 236 Fifth Avenue, Suite 400, |
|
| August 9, 2023 |
Restricted Stock Award Agreement dated June 13, 2023 between Brad Roberts and LifeMD, Inc. Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is entered into as of June 13, 2023 (the “Memorial Date”) between LifeMD, Inc. (the “Company”) and Brad Roberts (the “Employee”) memorializing the grant of restricted stock to Employee as set forth below (the “Grant Date”) WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common S |
|
| August 9, 2023 |
Consulting Services Agreement, dated June 14, 2023, by and between the Company and Robert Jindal Exhibit 10.5 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (“Consulting Agreement” or the “Agreement”) is made effective as of June 14, 2023 (the “Effective Date”), by and between Robert Jindal, having an address at 15040 Audubon Lakes Drive, Baton Rouge, LA 70810 (the “Consultant”) and LifeMD, Inc., a corporation with an address of 236 Fifth Avenue, Suite 400, New York, NY 1000 |
|
| August 9, 2023 |
Exhibit 10.3 EXHIBIT A LIFEMD, INC. DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT This Director and Officer Indemnification Agreement, dated as of June 13, 2023 (the “Agreement”), is made by and between LifeMD, Inc., a Delaware corporation (the “Company”), and Brad Roberts (the “Indemnitee”). RECITALS: A. The Delaware General Corporation Law provides that the business and affairs of a corporation |
|
| August 9, 2023 |
Exhibit 10.1 THIRD AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS THIRD AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Third Amendment”) is entered into as of June 13, 2023 (the “Third Amendment Effective Date”) by and between Brad Roberts, an individual and resident of the State of South Carolina, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact n |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| July 14, 2023 |
Exhibit 10.3 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of July 11, 2023 (the “Second Amendment Effective Date”) by and between Marc Benathen, an individual and resident of the State of New York, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Corpor |
|
| July 14, 2023 |
Restricted Stock Award Agreement dated July 11, 2023 between Marc Benathen and LifeMD, Inc Exhibit 10.4 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is made effective as of July 11, 2023 (the “Grant Date”) between LifeMD, Inc. (the “Company”) and Marc Benathen (the “Employee”). WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common Stock, $0.01 par value (“Shares”), subject to certain restrictions as set forth in this Agreem |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 29, 2023 |
Prospectus Supplement dated June 29, 2023 Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated June 22, 2021) Registration No. |
|
| June 22, 2023 |
Director Agreement, dated June 20, 2023 between LifeMD, Inc. and William J. Febbo Exhibit 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of June 20, 2023 (the “Agreement”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), and William Febbo, an individual with an address of 142 Calle Violeta, San Juan, Puerto Rico 00927 (the “Director”). WHEREAS, the Company and the Director desire to enter with respect to the appointment of the Director; WHEREAS, |
|
| June 22, 2023 |
Consulting Services Agreement, dated May 30, 2023, between LifeMD, Inc. and William J. Febbo Exhibit 10.4 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (“Consulting Agreement” or the “Agreement”) is made effective as of May 30, 2023 (the “Effective Date”), by and between William Febbo, having an address at 142 Calle Violeta, San Juan, Puerto Rico 00927 (the “Consultant”) and LifeMD, Inc., a corporation with an address of 236 Fifth Avenue, Suite 400, New York, NY 10001 ( |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 22, 2023 |
Restricted Stock Award Agreement, dated June 20, 2023, between LifeMD, Inc. and William J. Febbo Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT DIRECTORS THIS RESTRICTED STOCK AWARD (this “Agreement”) is granted as of June 20, 2023 (the “Grant Date”), and reflected in this RESTRICTED STOCK AWARD AGREEMENT (the “Agreement”) between LifeMD, Inc. (the “Company”), and William Febbo (the “Director”). WHEREAS, the Company desires to grant the Director, shares of the Company’s Common Sto |
|
| June 22, 2023 |
Non-Qualified Stock Option Agreement, dated June 20, 2023, between LifeMD, Inc. and William J. Febbo Exhibit 10.3 LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT DIRECTOR THIS NON-QUALIFIED STOCK OPTION is granted as of June 20, 2023 (the “Grant Date”), and reflected in this NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) by and between LifeMD, Inc. (the “Company”) and William Febbo the “Optionee”). WHEREAS, pursuant to the authority of the Board of Directors (the “Board”), the Company |
|
| June 22, 2023 |
LifeMD Appoints William J. Febbo to its Board of Directors Exhibit 99.1 LifeMD Appoints William J. Febbo to its Board of Directors NEW YORK, June 20, 2023 – LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (Nasdaq: OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-ca |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 20, 2023 |
Exhibit 10.3 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of June 15, 2023 (the “Second Amendment Effective Date”) by and between Eric H. Yecies, an individual and resident of the State of New Jersey, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Cor |
|
| June 20, 2023 |
Restricted Stock Award Agreement dated June 15, 2023 between Eric Yecies and LifeMD, Inc Exhibit 10.4 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is entered into as of June 15, 2023 (the “Memorial Date”) between LifeMD, Inc. (the “Company”) and Eric H. Yecies (the “Employee”) memorializing the grant of restricted stock to Employee as set forth below (the “Grant Date”) WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 27, 2023 |
PROSPECTUS SUPPLEMENT DATED MARCH 27, 2023 Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated June 22, 2021) Registration No. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 23, 2023 |
Form of Promissory Note issued to Avenue Venture Opportunities Exhibit 10.4 PROMISSORY NOTE [Note No. ] $ March 21, 2023 The undersigned (“Borrower”) promises to pay to the order of (“Lender”), at such place as Lender may designate in writing, in lawful money of the United States of America, the principal sum of Nine Million Dollars ($), with interest thereon from the date hereof until maturity, whether scheduled or accelerated, at a variable rate per annum e |
|
| March 23, 2023 |
LifeMD, Inc. Announces Closing of New $40 Million Credit Facility Exhibit 99.1 LifeMD, Inc. Announces Closing of New $40 Million Credit Facility NEW YORK, March 22, 2023 — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that the Company closed on a new senior secured credit facility with Avenue Capital. The credit agreement, which matures on October 1, 2026, provides up to $40 million in total term loan capital includ |
|
| March 23, 2023 |
Form of Warrant issued to Avenue Venture Opportunities Exhibit 10.3 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF (A) SUCH REGISTRATION, (B) AN OP |
|
| March 23, 2023 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 LOAN AND SECURITY AGREEMENT Dated as of March 21, 2023 between LIFEMD, INC., a Delaware corporation as “Borrower”, and AVENUE VENTURE OPPORTUNITIES FUND II, L.P., a Delaware limited partnership, (“Avenue 2”), as a lender, and AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (“Avenue”) as administrative agent and collateral agent (in such cap |
|
| March 23, 2023 |
Exhibit 10.2 SUPPLEMENT to the Loan and Security Agreement dated as of March 21, 2023 among LifeMD, Inc. (“Borrower”) Avenue Venture Opportunities Fund, L.P. II, L.P., a Delaware limited partnership (“Avenue 2”), as a lender and Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership (“Avenue” and, in its capacity as a lender, together with Avenue 2, each a “Lender” and collectivel |
|
| March 22, 2023 |
Exhibit 21.1 Subsidiaries of LifeMD, Inc. Subsidiary Name Jurisdiction of Incorporation WorkSimpli Software LLC Puerto Rico Conversion Labs PR LLC Puerto Rico Cleared Technologies, PBC Delaware Springbox Technologies LLC Delaware Taylor Technologies Inc Delaware |
|
| March 22, 2023 |
LifeMD, Inc. Amended and Restated 2020 Equity and Incentive Plan Exhibit 4.5 LIFEMD, INC. AMENDED AND RESTATED 2020 EQUITY AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN: DEFINITIONS The name of the plan is the LIFEMD, INC. AMENDED AND RESTATED 2020 EQUITY AND INCENTIVE PLAN (the “Plan”). The purpose of the Plan is to encourage, retain and enable the officers, employees, directors, Consultants and other key persons of LIFEMD, INC., a Delaware corpora |
|
| March 22, 2023 |
Restricted Stock Award Agreement between Jessica Friedeman and LifeMD, Inc. dated January 3, 2023 Exhibit 10.83 EXHIBIT A LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT THIS AGREEMENT (this “Agreement”) is made as of January 3, 2023 (the “Grant Date”) between LifeMD, Inc. (the “Company”) and Jessica Friedeman (the “Employee”). WHEREAS, the Company desires to grant the Employee, shares of the Company’s Common Stock, $0.01 par value (“Shares”), subject to certain restrictions as set forth in this |
|
| March 22, 2023 |
EX-10.84 6 ex10-84.htm Exhibit 10.84 EXHIBIT B LIFEMD, INC. DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT This Director and Officer Indemnification Agreement, dated as of January 3, 2023 (the “Agreement”), is made by and between LifeMD, Inc., a Delaware corporation (the “Company”), and Jessica Friedeman (the “Indemnitee”). RECITALS: A. The Delaware General Corporation Law provides that the busine |
|
| March 22, 2023 |
Certificate of Incorporation, As Amended Exhibit 3.1 |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39785 LIFEMD, INC. (E |
|
| March 22, 2023 |
Employment Agreement between Jessica Friedeman and LifeMD, Inc. dated January 3, 2023 Exhibit 10.82 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made effective as of January 3, 2023, (the “Effective Date”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), having corporate headquarters at 236 Fifth Avenue, Suite 400, New York, NY 10001, and Jessica Friedeman, an individual and resident of the State of New York with an address at 38 Hallmam Road |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| February 10, 2023 |
Non-Qualified Stock Option Agreement, dated February 9, 2023, between LifeMD, Inc. and Joan LaRovere Exhibit 10.3 LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT DIRECTOR THIS NON-QUALIFIED STOCK OPTION is granted as of February 9, 2023 (the “Grant Date”), and reflected in this NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) by and between LifeMD, Inc. (the “Company”) and Dr. Joan LaRovere (the “Optionee”). WHEREAS, pursuant to the authority of the Board of Directors (the “Board”), the |
|
| February 10, 2023 |
Director Agreement, dated February 9, 2023, between LifeMD, Inc. and Joan LaRovere EX-10.1 2 ex10-1.htm Exhibit 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of February 9, 2023 (the “Agreement”), by and between LifeMD, Inc., a Delaware corporation (the “Company”), and Dr. Joan LaRovere, an individual with an address of [***] (the “Director”). WHEREAS, the Company and the Director desire to enter with respect to the appointment of the Director; WHEREAS, the Director |
|
| February 10, 2023 |
Restricted Stock Award Agreement, dated February 9, 2023, between LifeMD, Inc. and Joan LaRovere EX-10.2 3 ex10-2.htm Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT DIRECTORS THIS RESTRICTED STOCK AWARD (this “Agreement”) is granted as of February 9, 2023 (the “Grant Date”), and reflected in this RESTRICTED STOCK AWARD AGREEMENT (the “Agreement”) between LifeMD, Inc. (the “Company”), and Dr. Joan LaRovere (the “Director”). WHEREAS, the Company desires to grant the Director, shares |
|
| February 10, 2023 |
Exhibit 2.1 FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT between LIFEMD, INC., and CLEARED TECHNOLOGIES, PBC, and THE SELLERS LISTED ON SCHEDULE 1 OF THE AGREEMENT This FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT (the “Amendment”) is made effective as of February 4, 2023 (the “Effective Date”), between the Sellers identified on Schedule 1 of the Agreement (as defined below) (the “Sellers”) and Life |
|
| February 10, 2023 |
LifeMD Appoints Dr. Joan LaRovere to its Board of Directors Exhibit 99.1 LifeMD Appoints Dr. Joan LaRovere to its Board of Directors NEW YORK, February 10, 2023 — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Dr. Joan LaRovere to its Board of Directors. With Dr. LaRovere’s appointment, LifeMD’s Board will comprise nine directors, seven of whom are independent. “We are pleased to welcome Dr. |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| December 21, 2022 |
Restricted Stock Award Agreement, dated December 15, 2022, between LifeMD, Inc. and Kate Walsh Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT DIRECTORS THIS RESTRICTED STOCK AWARD (this ?Agreement?) is granted as of December 15, 2022 (the ?Grant Date?), and reflected in this RESTRICTED STOCK AWARD AGREEMENT (the ?Agreement?) between LifeMD, Inc. (the ?Company?), and Kate Walsh (the ?Director?). WHEREAS, the Company desires to grant the Director, shares of the Company?s Common St |
|
| December 21, 2022 |
Non-Qualified Stock Option Agreement, dated December 15, 2022, between LifeMD, Inc. and Kate Walsh Exhibit 10.3 LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT DIRECTOR THIS NON-QUALIFIED STOCK OPTION is granted as of December 15, 2022 (the ?Grant Date?), and reflected in this NON-QUALIFIED STOCK OPTION AGREEMENT (this ?Agreement?) by and between LifeMD, Inc. (the ?Company?) and Kate Walsh (the ?Optionee?). WHEREAS, pursuant to the authority of the Board of Directors (the ?Board?), the Compan |
|
| December 21, 2022 |
Director Agreement, dated December 15, 2022, between LifeMD, Inc. and Kate Walsh Exhibit 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of December 15, 2022 (the ?Agreement?), by and between LifeMD, Inc., a Delaware corporation (the ?Company?), and Kate Walsh, an individual with an address of 5 Union Park Street, Boston, MA 02118 (the ?Director?). WHEREAS, the Company and the Director desire to enter with respect to the appointment of the Director; WHEREAS, the Dir |
|
| November 14, 2022 |
Presentation Material dated November 2022 Exhibit 99.1 |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Ex |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 20, 2022 |
Exhibit 10.3 LIFEMD, INC. NON-QUALIFIED STOCK OPTION AGREEMENT DIRECTOR THIS NON-QUALIFIED STOCK OPTION is granted as of Sept. 14, 2022 (the ?Grant Date?), and reflected in this NON-QUALIFIED STOCK OPTION AGREEMENT (this ?Agreement?) by and between LifeMD, Inc. (the ?Company?) and Robert Jindal (the ?Optionee?). WHEREAS, pursuant to the authority of the Board of Directors (the ?Board?), the Compan |
|
| September 20, 2022 |
Restricted Stock Award Agreement, dated September 14, 2022, between LifeMD, Inc. and Robert Jindal Exhibit 10.2 LIFEMD, INC. RESTRICTED STOCK AWARD AGREEMENT DIRECTORS THIS RESTRICTED STOCK AWARD (this ?Agreement?) is granted as of Sept. 14, 2022 (the ?Grant Date?), and reflected in this RESTRICTED STOCK AWARD AGREEMENT (the ?Agreement?) between LifeMD, Inc. (the ?Company?), and Robert Jindal (the ?Director?). WHEREAS, the Company desires to grant the Director, shares of the Company?s Common St |
|
| September 20, 2022 |
Director Agreement, dated September 14, 2022, between LifeMD, Inc. and Robert Jindal Exhibit 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of September 14, 2022 (the ?Agreement?), by and between LifeMD, Inc., a Delaware corporation (the ?Company?), and Robert Jindal, an individual with an address of 15040 Audubon Lakes Drive, Baton Rouge, LA 70810 (the ?Director?). WHEREAS, the Company and the Director desire to enter with respect to the appointment of the Director; W |
|
| September 20, 2022 |
LifeMD Appoints Bobby Jindal to the Board of Directors Exhibit 99.1 LifeMD Appoints Bobby Jindal to the Board of Directors NEW YORK, September 20, 2022 ? LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, is pleased to announce its appointment of Bobby Jindal, the 55th Governor of the State of Louisiana, to its board of directors. Mr. Jindal was elected as the nation?s youngest governor in 2007 and spent two terms as Louisian |
|
| September 14, 2022 |
Letter from Friedman LLP, to the Securities and Exchange Commission, dated September 14, 2022 Exhibit 16.1 September 14, 2022, Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read the statements made by LifeMD, Inc. under Item 4.01 of its Form 8-K dated September 14, 2022. We agree with the statements concerning our firm in such Form 8-K; we are not in a position to agree or disagree with other statements of LifeMD, Inc. contained therein. |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| August 17, 2022 |
PROSPECTUS LIFEMD INC. 152,912 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-255586 PROSPECTUS LIFEMD INC. 152,912 Shares of Common Stock This prospectus relates to the offering and resale by the Investors or their registered assigns (each a ?Selling Stockholder? and collectively the ?Selling Stockholders?) identified herein of up to 152,912 shares of Common Stock of the Company, issued pursuant to that certain Securiti |
|
| August 17, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-250985 PROSPECTUS LIFEMD INC. 809,139 Shares of Common Stock 35,369 Shares of Common Stock underlying Common Stock Purchase Warrants This prospectus relates to the offering and resale by the Investors, the Placement Agent or their registered assigns (each a ?Selling Stockholder? and collectively the ?Selling Stockholders?) identified herein of |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact n |
|
| July 1, 2022 |
As filed with the Securities and Exchange Commission on July 1, 2022 As filed with the Securities and Exchange Commission on July 1, 2022 Registration No. |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-39785 LIFEMD, INC. (Exact |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 29, 2022 |
LifeMD, Inc. Amended and Restated 2020 Equity and Incentive Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 28, 2022 |
As filed with the Securities and Exchange Commission on March 28, 2022 As filed with the Securities and Exchange Commission on March 28, 2022 Registration No. |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39785 LIFEMD, INC. (Exact na |
|
| March 7, 2022 |
Exhibit 21.1 Subsidiaries of LifeMD, Inc. Subsidiary Name Jurisdiction of Incorporation WorkSimpli Software, LLC Puerto Rico Conversion Labs PR LLC Puerto Rico |
|
| March 7, 2022 |
Exhibit 4.9 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Set forth below is the description of each class of securities of LifeMD, Inc. (the ?Company?) outstanding as of December 31, 2021. The following description summarizes the most important terms of these securities. This summary does not purport to be complete and is qualified |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| February 22, 2022 |
Exhibit 2.4 |
|
| February 22, 2022 |
Exhibit 2.5 |
|
| February 22, 2022 |
Presentation Material dated February 2022 Exhibit 99.1 |
|
| February 22, 2022 |
EX-2.3 4 ex2-3.htm Exhibit 2.3 |
|
| February 22, 2022 |
Exhibit 2.1 |
|
| February 22, 2022 |
Promissory Note dated as of October 19, 2021, issued by WorkSimpli Software LLC to LifeMD, Inc. Exhibit 2.2 |
|
| February 22, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| February 7, 2022 |
Employment Agreement dated March 15, 2021 between Maria Stan and LifeMD, Inc. Exhibit 10.2 |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| February 7, 2022 |
Exhibit 10.1 |
|
| February 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| February 2, 2022 |
Exhibit 10.1 |
|
| February 2, 2022 |
EX-10.2 3 ex10-2.htm Exhibit 10.2 |
|
| January 19, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| January 19, 2022 |
Exhibit 99.1 LifeMD Provides Initial FY2022 Guidance and Announces Preliminary FY2021 Revenues Total FY2022 revenue anticipated to be in the range of $142 to $148 million Remains on track to achieve Adjusted EBITDA profitability by Q4 2022 Reports preliminary fourth quarter revenue of $27.4 million and FY2021 consolidated revenue of $92.9 million, +149% vs. year-ago period NEW YORK, Jan. 19, 2022 |
|
| January 19, 2022 |
Presentation Material dated January 2022 Exhibit 99.1 |
|
| January 19, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| January 12, 2022 |
Stock Purchase Agreement, dated as of January 11, 2022 Exhibit 2.1 STOCK PURCHASE AGREEMENT between LIFEMD, INC., and CLEARED TECHNOLOGIES, PBC, and The Sellers listed on Schedule 1 attached dated as of January 11, 2022 TABLE OF CONTENTS ARTICLE I DEFINITIONS 6 ARTICLE II PURCHASE AND SALE 20 Section 2.01 Purchase and Sale. 20 Section 2.02 Purchase Price. 20 Section 2.03 Transactions to be Effected at the Closing. 20 Section 2.04 Purchase Price Adjust |
|
| January 12, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE January 12, 2022 Contact: Eric Herman [email protected] LifeMD Expands Patient Offerings by Acquiring Leading Allergy Telehealth Platform Acquisition of Cleared Further Diversifies LifeMD?s Telehealth Offerings to Encompass Allergy, Asthma, and Immunology Acquisition Expected to Synergize with LifeMD Virtual Primary Care Platform Acquisition Expected to Contribu |
|
| January 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission File |
|
| November 10, 2021 |
Renewed Director Agreement, dated September 7, 2021, by and between LifeMD, Inc. and John Strawn Exhibit 10.3 |
|
| November 10, 2021 |
EX-10.4 3 ex10-4.htm Exhibit 10.4 |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 000-55857 LIFEMD, INC. (Ex |
|
| November 10, 2021 |
EX-10.5 4 ex10-5.htm Exhibit 10.5 |
|
| October 4, 2021 |
Exhibit 1.1 3,333,334 Shares LIFEMD, INC. Common Stock UNDERWRITING AGREEMENT September 28, 2021 September 28, 2021 B. Riley Securities, Inc. As Representative of the several Underwriters c/o B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, New York 100171 Ladies and Gentlemen: LifeMD, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to the several Underwrite |
|
| October 4, 2021 |
Exhibit 99.6 LifeMD Announces Closing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock NEW YORK, October 4, 2021 ? LifeMD, Inc. (?the Company?) (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company today announced the closing of its previously announced underwritten registered public offering of 1,400,000 shares of its 8.875% Series A Cum |
|
| October 4, 2021 |
LifeMD Announces Pricing of Public Offering of Common Stock EX-99.3 13 ex99-3.htm Exhibit 99.3 LifeMD Announces Pricing of Public Offering of Common Stock NEW YORK, September 28, 2021 – LifeMD, Inc. (the “Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the pricing of its previously announced underwritten registered public offering of 3,333,334 shares of its common stock, par value $0.01 per share, for gross proceed |
|
| October 4, 2021 |
LifeMD Announces Launch of Public Offering of Common Stock Exhibit 99.1 LifeMD Announces Launch of Public Offering of Common Stock NEW YORK, September 28, 2021 ? LifeMD, Inc. (the ?Company?) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that it has commenced an underwritten registered public offering of shares of its common stock, par value $0.01 per share. In connection with this offering, the Company expects to grant th |
|
| October 4, 2021 |
LifeMD Announces Closing of Public Offering of Common Stock and Exercise of the Underwriters’ Option Exhibit 99.5 LifeMD Announces Closing of Public Offering of Common Stock and Exercise of the Underwriters? Option NEW YORK, October 4, 2021 ? LifeMD, Inc. (the ?Company?) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the closing of its previously announced underwritten registered public offering of 3,833,334 shares of its common stock, par value $0.01 per share, w |
|
| October 4, 2021 |
Exhibit 99.4 LifeMD Announces Pricing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock NEW YORK, September 29, 2021 ? LifeMD, Inc. (?the Company?) (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company today announced the pricing of its previously announced underwritten registered public offering of 1,400,000 shares of its 8.875% Series A |
|
| October 4, 2021 |
LifeMD Announces Launch of Public Offering of 1,400,000 Shares of Preferred Stock Exhibit 99.2 LifeMD Announces Launch of Public Offering of 1,400,000 Shares of Preferred Stock NEW YORK, September 28, 2021 ? LifeMD, Inc. (?the Company?) (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company today announced it has commenced an underwritten registered public offering of 1,400,000 shares of its Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per sh |
|
| October 4, 2021 |
Exhibit 1.2 1,400,000 Shares LIFEMD, INC. 8.875% Series A Cumulative Perpetual Preferred Stock UNDERWRITING AGREEMENT September 29, 2021 September 29, 2021 B. Riley Securities, Inc. As Representative of the several Underwriters c/o B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, New York 100171 Ladies and Gentlemen: LifeMD, Inc., a Delaware corporation (the ?Company?), proposes to |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2021 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 4, 2021 |
Certificate of Designation for Series A Preferred Stock Exhibit 1.3 CERTIFICATE OF DESIGNATION OF 8.875% SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK OF LIFEMD, INC. Pursuant to the General Corporation Law of the State of Delaware LifeMD, Inc., a Delaware corporation (the ?Corporation?), hereby certifies, that pursuant to the authority expressly vested in the Board of Directors of the Corporation (the ?Board?) by the Certificate of Incorporation of th |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 LIFEMD, INC. (Exact name of registrant as specified in its charter) Delaware 76-0238453 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 800 Third |
|
| October 1, 2021 |
424B5 1 form424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-256911 PROSPECTUS SUPPLEMENT (To Prospectus dated June 22, 2021) LIFEMD, INC. 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock (Liquidation Preference of $25.00 Per Share) We are offering for sale 1,400,000 shares of our 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per sha |
|
| September 30, 2021 |
Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration No. 333-256911 LIFEMD, INC. 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock (Liquidation Amount of $25.00 Per Share) Final Term Sheet Issuer: LifeMD, Inc. Securities: 8.875% Series A Cumulative Perpetual Preferred Stock (the ?Series A Preferred Stock?) Number of Shares: 1,400,000 Shares of Series A Pref |
|
| September 30, 2021 |
LIFEMD, INC. 3,333,334 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-256911 PROSPECTUS SUPPLEMENT (To Prospectus dated June 22, 2021) LIFEMD, INC. 3,333,334 Shares of Common Stock We are offering for sale 3,333,334 shares of our common stock. The number of shares sold in this offering and the public offering price will be determined through negotiation between us and the underwriters in the offering. We have gra |
|
| September 28, 2021 |
Subject to Completion, dated September 28, 2021 424B5 1 form424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-256911 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying base prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the a |
|
| September 28, 2021 |
Subject to Completion, dated September 28, 2021 Filed Pursuant to Rule 424(b)(5) Registration No. 333-256911 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying base prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying base prosp |
|
| September 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 27, 2021 |
Presentation Material dated September 27, 2021 EX-99.1 2 ex99-1.htm Exhibit 99.1 |
|
| September 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 LIFEMD, INC. (Exact name of Registrant as specified in its charter) Delaware 001-39785 76-0238453 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 22, 2021 |
Exhibit 99.1 |
|
| September 13, 2021 |
Director Agreement between LifeMD, Inc. and Naveen Bhatia, dated September 8, 2021 EX-10.1 2 ex10-1.htm Exhibit 10.1 |
|
| September 13, 2021 |
Exhibit 99.1 LifeMD Appoints Seasoned Investor Naveen Bhatia to Board of Directors Industry veteran brings deep financial and management expertise to LifeMD as company continues to transform healthcare and build out growing telehealth platform NEW YORK, September 13, 2021 ? LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced its appointment of Naveen Bhatia |
|
| September 13, 2021 |
Consulting Services Agreement between Naveen Bhatia and LifeMD, Inc., dated September 8, 2021 EX-10.2 3 ex10-2.htm Exhibit 10.2 |
